Heron Therapeutics stock at EUR 0.34 as Nasdaq move reaches 4.4 percent

Published on 10/15/2026 at 21:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 37.70 million on June 30, 2026. Heron Therapeutics stock costs EUR 0.34 on October 15, 2026, up 4.4 percent on Nasdaq.

Nasdaq trading turns higher

Heron Therapeutics traded 4.42 percent higher on Nasdaq on October 15, 2026.
Q2 2026 net product sales reached USD 37.70 million, while gross margin was 69.30 percent.
Heron Therapeutics stock costs EUR 0.34 at Lang & Schwarz on October 15, 2026 at 9:16 p.m. CEST, up 4.42 percent on Nasdaq.
Heron Therapeutics is estimated to report third-quarter 2026 results on November 3, 2026.

HRTX, US4277461020, Illustration mit AI erstellt.

Heron Therapeutics stock was up 4.42 percent on Nasdaq on October 15, 2026, while the euro quote stood at EUR 0.34 after hours. At Lang & Schwarz, the stock was trading at EUR 0.34 on October 15, 2026 at 9:16 p.m. CEST; the Nasdaq quote was USD 0.38 at 3:22 p.m. EDT.

Q2 revenue reached USD 37.70 million

The latest reported quarter gives the price move a difficult operating backdrop. According to MetaTrader, Heron reported USD 37.70 million in net product sales for the quarter ended June 30, 2026, versus USD 37.20 million a year earlier. Gross profit declined to USD 26.10 million from USD 27.30 million, and gross margin fell to 69.30 percent from 73.50 percent.

52-week range remains wide

The Nasdaq quote's intraday range ran from USD 0.36 to USD 0.38 on October 15, 2026, with volume of 1,053,158 shares against an average of 2,494,809 shares. The 52-week range was USD 0.26 to USD 1.58, leaving the stock 75.95 percent below its high and 46.15 percent above its low. The market capitalization was USD 71.60 million.

Heron's latest filing also reported a net loss of USD 5.50 million for the second quarter, compared with USD 2.40 million a year earlier. The six-month net loss was USD 13.60 million, while cash and investments stood at USD 42.70 million as of June 30, 2026. On September 23, 2026, the company entered a multi-product development and licensing agreement, according to MetaTrader.

Valuation and November 3 report

MarketWatch listed a Hold recommendation, two ratings and an average target of USD 0.34 on October 15, 2026. The target was 10.53 percent below the Nasdaq price of USD 0.38 at the time of the quote. MarketBeat listed November 3, 2026 as the estimated date for third-quarter results, with an expected revenue figure of USD 37.50 million and adjusted earnings per share of minus USD 0.03.

Comparison with peers

HRTX: plus 4.42 percent, P/E minus 1.99, market capitalization USD 71.60 million

ANI Pharmaceuticals (Nasdaq, USD): plus 3.13 percent, P/E 15.64, market capitalization USD 1.70 billion

Amphastar Pharmaceuticals (Nasdaq, USD): plus 2.19 percent, P/E 15.78, market capitalization USD 1.10 billion

Price and upcoming results

Heron Therapeutics is trading near the bottom of its 52-week range, while its next scheduled reporting date gives investors a concrete calendar marker. The combination of a 69.30 percent gross margin and a second-quarter net loss of USD 5.50 million leaves profitability as the key operating measure.

At Lang & Schwarz, Heron Therapeutics was trading at EUR 0.34 on October 15, 2026 at 9:16 p.m. CEST. The Nasdaq quote was USD 0.38 at 3:22 p.m. EDT, up 4.42 percent on the day.

The further course of trading is shown by the continuously updated real-time quote of Heron Therapeutics stock.